FibroBiologics (NASDAQ: FBLG) announced the appointment of Jason D. Davis, CPA, as chief financial officer (CFO), effective immediately.
Bringing extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives, Mr. Davis recently served as CFO of Virax Biolabs.
Pete O’Heeron, founder, chairman, and CEO of FibroBiologics, stated, “Jason brings exactly the kind of experience and leadership we need at this pivotal moment. His deep understanding of public company operations and capital markets isn’t just helpful — it’s a force multiplier as we move our lead program into the clinic. He knows how to raise capital in a complex biotech environment, and that makes him a critical part of our mission to drive long-term innovation and deliver exceptional value to shareholders.”
Mr. Davis remarked, “FibroBiologics, with its fibroblast-based platform, strong intellectual property portfolio, and well-defined clinical strategy, offers a truly differentiated approach to the development of therapeutics and potential cures for chronic diseases, and has all the elements of a high-growth, high-impact enterprise. I’m excited to bring my experience in public company finance to the table as we execute, scale, and deliver meaningful value — not just for shareholders, but for patients around the world.”
